Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits
暂无分享,去创建一个
[1] J. Wilkinson,et al. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge? , 2012, Journal of clinical pharmacology.
[2] D. Galimberti,et al. Progress in Alzheimer’s disease , 2012, Journal of Neurology.
[3] Zhong Wang,et al. Next-generation transcriptome assembly , 2011, Nature Reviews Genetics.
[4] L. Defebvre,et al. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation , 2011, Neurobiology of Aging.
[5] Pei Wang,et al. Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease , 2011, Neurobiology of Disease.
[6] Y. Ohyagi. Apomorphine treatment in Alzheimer's mice promoting amyloid-beta degradation , 2011, Alzheimer's & Dementia.
[7] David Gomez-Cabrero,et al. ParkDB: a Parkinson’s disease gene expression database , 2011, Database J. Biol. Databases Curation.
[8] Daiga Heisters,et al. Parkinson's: symptoms, treatments and research. , 2011, British journal of nursing.
[9] A. Young,et al. Milestones in Huntington disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[10] J. Kril,et al. Understanding the pathogenesis of Alzheimer’s disease: will RNA‐Seq realize the promise of transcriptomics? , 2011, Journal of neurochemistry.
[11] Mohamad Saad,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[12] H. Federoff,et al. Therapeutic potential of vaccines for Alzheimer's disease. , 2011, Immunotherapy.
[13] F. Jirik,et al. Prion protein expression level alters regional copper, iron and zinc content in the mouse brain. , 2011, Metallomics : integrated biometal science.
[14] T. Tabira,et al. Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation , 2011, Annals of neurology.
[15] M. Menéndez-González,et al. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. , 2011, Current pharmaceutical design.
[16] M. Wilkins,et al. Whole Transcriptome Sequencing Reveals Gene Expression and Splicing Differences in Brain Regions Affected by Alzheimer's Disease , 2011, PloS one.
[17] L. Bubacco,et al. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? , 2011, Molecular Neurodegeneration.
[18] Sandro Sorbi,et al. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. , 2011, Archives of neurology.
[19] Huaxi Xu,et al. APP processing in Alzheimer's disease , 2011, Molecular Brain.
[20] Xiongwei Zhu,et al. Frontiers in Alzheimer’s disease therapeutics , 2011, Therapeutic advances in chronic disease.
[21] T. Amit,et al. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. , 2010, Progress in neurobiology.
[22] Manuel B. Graeber,et al. PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.
[23] M. Zampieri,et al. Gene expression profiling to identify druggable targets in prion diseases , 2010, Expert opinion on drug discovery.
[24] Anil Kumar,et al. Huntington’s disease: pathogenesis to animal models , 2010, Pharmacological reports : PR.
[25] C. Tanner,et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.
[26] G. Legname,et al. De novo mammalian prion synthesis , 2009, Prion.
[27] Lisa M. Miller,et al. Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease , 2009, NeuroImage.
[28] Isidro Ferrer,et al. Unexpected expression of α- and β-globin in mesencephalic dopaminergic neurons and glial cells , 2009, Proceedings of the National Academy of Sciences.
[29] J. Olcese,et al. Protection against cognitive deficits and markers of neurodegeneration by long‐term oral administration of melatonin in a transgenic model of Alzheimer disease , 2009, Journal of pineal research.
[30] M. Sano,et al. An update on treatment and prevention strategies for Alzheimer’s disease , 2009, Current neurology and neuroscience reports.
[31] V. Daggett,et al. The consequences of pathogenic mutations to the human prion protein. , 2009, Protein engineering, design & selection : PEDS.
[32] Mark A. Smith,et al. Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease , 2009, Neuroscience Letters.
[33] M. Graeber. Biomarkers for Parkinson's disease , 2009, Experimental Neurology.
[34] Yongliang Yang,et al. Target discovery from data mining approaches. , 2009, Drug discovery today.
[35] B. Mollenhauer,et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.
[36] I. Schlesinger,et al. Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[37] A. Kurz,et al. Parkinson patient fibroblasts show increased alpha-synuclein expression , 2008, Experimental Neurology.
[38] Mary Sano,et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.
[39] A. Lang,et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.
[40] Eric M Reiman,et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. , 2008, Physiological genomics.
[41] L. Rydzewska,et al. Systematic review of therapeutic interventions in human prion disease , 2008, Neurology.
[42] H. Diana Rosas,et al. Neuroprotection for Huntington’s disease: Ready, set, slow , 2008, Neurotherapeutics.
[43] R. Montironi,et al. Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. , 2008, International journal of clinical and experimental pathology.
[44] R. Faull,et al. Assessing RNA quality in postmortem human brain tissue. , 2008, Experimental and molecular pathology.
[45] Adriano Aguzzi,et al. Molecular mechanisms of prion pathogenesis. , 2008, Annual review of pathology.
[46] S. Leurgans,et al. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment , 2007, Annals of neurology.
[47] George Perry,et al. Evidence for the role of luteinizing hormone in Alzheimer disease. , 2007, Endocrine, metabolic & immune disorders drug targets.
[48] John Collinge,et al. A General Model of Prion Strains and Their Pathogenicity , 2007, Science.
[49] J. Cha,et al. Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.
[50] Bjørn K. Alsberg,et al. A framework for significance analysis of gene expression data using dimension reduction methods , 2007, BMC Bioinformatics.
[51] Kathryn Ziegler-Graham,et al. Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.
[52] Paul Greengard,et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies , 2007, Proceedings of the National Academy of Sciences.
[53] M. Rezak. Current pharmacotherapeutic treatment options in Parkinson's disease. , 2007, Disease-a-month : DM.
[54] Alun Williams,et al. Simvastatin treatment prolongs the survival of scrapie-infected mice , 2007, Neuroreport.
[55] K. Lunetta,et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.
[56] J. Growdon,et al. Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.
[57] F. Cohen,et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes , 2006, Proceedings of the National Academy of Sciences.
[58] D. Lütjohann,et al. Simvastatin prolongs survival times in prion infections of the central nervous system. , 2006, Biochemical and biophysical research communications.
[59] J. Kleinman,et al. Critical Factors in Gene Expression in Postmortem Human Brain: Focus on Studies in Schizophrenia , 2006, Biological Psychiatry.
[60] T. Montine,et al. LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.
[61] J. Collinge,et al. A systematic review of prion therapeutics in experimental models. , 2006, Brain : a journal of neurology.
[62] A. Bush,et al. The Role of Metal Ions in Neurology. An Introduction , 2006 .
[63] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[64] L. Moran,et al. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.
[65] Charles M Perou,et al. Evaluating the comparability of gene expression in blood and brain , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[66] J. Olson,et al. Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.
[67] D. Allsop,et al. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] L. Moran,et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.
[69] Ian J. Reynolds,et al. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures , 2005, Neurobiology of Disease.
[70] Jingwen Liu,et al. Synuclein Gamma Inhibits the Mitotic Checkpoint Function and Promotes Chromosomal Instability of Breast Cancer Cells , 2005, Breast Cancer Research and Treatment.
[71] J. Lucas,et al. Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.
[72] A. Matus. MARCKS for Maintenance in Dendritic Spines , 2005, Neuron.
[73] S. Mandel,et al. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin‐Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC‐70 , 2005, Annals of the New York Academy of Sciences.
[74] H. Kretzschmar,et al. Cerebral gene expression profiles in sporadic Creutzfeldt–Jakob disease , 2005, Annals of neurology.
[75] A. Hannan. Novel therapeutic targets for Huntington’s disease , 2005, Expert opinion on therapeutic targets.
[76] R. Brookmeyer,et al. Reduced risk of Alzheimer’s disease with high folate intake: The Baltimore Longitudinal Study of Aging , 2005, Alzheimer's & Dementia.
[77] Ling Lin,et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.
[78] R. Jensen,et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. , 2005, Archives of neurology.
[79] W. Noble,et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[80] G. Pasinetti,et al. From proteomics to biomarker discovery in Alzheimer's disease , 2005, Brain Research Reviews.
[81] N. Hattori,et al. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease , 2005, Neurology.
[82] J. Collins,et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks , 2005, Nature Biotechnology.
[83] N. Greig,et al. Inhibition of P53-related apoptosis had no effect on PrPSc accumulation and prion disease incubation time , 2005, Neurobiology of Disease.
[84] R. Dingledine,et al. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism , 2005, Neurobiology of Disease.
[85] J. Grimm,et al. Molecular basis for catecholaminergic neuron diversity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[86] A. Levey,et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. , 2004, Archives of neurology.
[87] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[88] M. Beal,et al. Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.
[89] Joachim Klose,et al. Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.
[90] B. Winblad,et al. Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population , 2004, Neuroepidemiology.
[91] M. Salmona,et al. Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity* , 2004, Journal of Biological Chemistry.
[92] C. Lines,et al. Rofecoxib , 2004, Neurology.
[93] R. Yasuda,et al. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.
[94] E. Sigurdsson,et al. Copper Chelation Delays the Onset of Prion Disease* , 2003, Journal of Biological Chemistry.
[95] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[96] Patrik Brundin,et al. Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.
[97] J. Collins,et al. Inferring Genetic Networks and Identifying Compound Mode of Action via Expression Profiling , 2003, Science.
[98] K. Davis,et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.
[99] Michael P H Stumpf,et al. Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics , 2003, Science.
[100] P. Julien,et al. Lipoprotein Lipase Affects the Survival and Differentiation of Neural Cells Exposed to Very Low Density Lipoprotein* , 2003, The Journal of Biological Chemistry.
[101] P. Coleman,et al. Defects in expression of genes related to synaptic vesicle traffickingin frontal cortex of Alzheimer’s disease , 2003, Neurobiology of Disease.
[102] H. Lehrach,et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[103] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[104] M. Ball,et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.
[105] R. Hébert,et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. , 2002, American journal of epidemiology.
[106] J. Drisko. The Use of Antioxidants in Transmissible Spongiform Encephalopathies: A Case Report , 2002, Journal of the American College of Nutrition.
[107] Danh V. Nguyen,et al. Tumor classification by partial least squares using microarray gene expression data , 2002, Bioinform..
[108] J M Lee,et al. A gene expression profile of Alzheimer's disease. , 2001, DNA and cell biology.
[109] M. Murphy,et al. Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction , 2001, Expert opinion on biological therapy.
[110] T. Sherer,et al. Complex I and Parkinson's Disease , 2001, IUBMB life.
[111] P. O'Brien,et al. Elevated gonadotropin levels in patients with Alzheimer disease. , 2001, Mayo Clinic proceedings.
[112] P. Scheltens,et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study , 2001, The Lancet.
[113] A. Czernik,et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique , 2001, Neuroscience Letters.
[114] J. Parks,et al. Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA‐receptor and nitric‐oxide‐synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro , 2001, Journal of neurochemistry.
[115] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[116] H J Koch,et al. A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.
[117] Ash A. Alizadeh,et al. 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns , 2000, Genome Biology.
[118] Atkinson,et al. An Association of Elevated Serum Gonadotropin Concentrations and Alzheimer Disease? , 2000, Journal of neuroendocrinology.
[119] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[120] S. Kuroda,et al. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson’s disease: relationship to clinical data , 1999, Journal of the Neurological Sciences.
[121] Stanley B. Prusiner,et al. Nobel Lecture: Prions , 1998 .
[122] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[123] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[124] H. Ushijima,et al. Effect of Flupirtine on Bcl-2 and Glutathione Level in Neuronal Cells Treatedin Vitrowith the Prion Protein Fragment (PrP106-126) , 1997, Experimental Neurology.
[125] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[126] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[127] S. Prusiner,et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform [published erratum appears in J Cell Biol 1995 Jul;130(2):501] , 1995, The Journal of cell biology.
[128] G. Macchi,et al. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. , 1992, Journal of Infectious Diseases.
[129] Christopher A. Ross,et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.
[130] P. Casaccia,et al. Amphotericin B: a novel class of antiscrapie drugs. , 1989, The Journal of infectious diseases.
[131] W. Gibb,et al. THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE , 1989, Neuropathology and applied neurobiology.
[132] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[133] D. Schlessinger,et al. Interaction of plasma proteins and lipoproteins with amphotericin B. , 1984, The Journal of infectious diseases.
[134] L. Schiffer,et al. Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.
[135] Katunina Ea,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[136] R. Uitti,et al. Autosomal dominant Parkinson's disease. , 2012, Parkinsonism & related disorders.
[137] Solve Sæbø,et al. A gene expression pattern in blood for the early detection of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[138] S. Krobitsch,et al. Huntington's disease: From molecular basis to therapeutic advances. , 2011, The international journal of biochemistry & cell biology.
[139] M. Gerstein,et al. RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.
[140] D. Blacker,et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.
[141] S. Dunnett,et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.
[142] Deborah Gustafson,et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.
[143] A. Schapira,et al. Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.
[144] A. Singleton,et al. alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.
[145] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[146] G. Halliday,et al. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans , 1996, The Journal of comparative neurology.
[147] A. Lbert,et al. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .